Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: Antimicrobial Resistance - EOI

McMaster University

$10,000.00

Developing a strain-specific test for rapid diagnosis of Clostridium difficile

EF 2016-17

Résumé
Clostridium difficile causes severe diarrhoea and is the main culprit for healthcare associated infections. The emergence of a new hypervirulent strain of C. difficile, known as NAP1, in recent years has caused a significant rise in the incidence and severity of infection. This is of major concern for hospitals worldwide as the technologies for detecting NAP1 are lagging behind the spread of this epidemic strain. Consequently, the rate of C. difficile infection (CDI) has doubled in the last few years and is costing the global healthcare system more than 6 billion dollars annually. In Canada, there has been a 5-fold increase in deaths directly related to C. difficile over the last decade. The inefficient process of identifying NAP1 prolongs patient hospital stay and increases the risk of transmission to other patients. Early detection of NAP1 is crucial for preventing outbreaks and overall management of infections, particularly since compared to other CDIs NAP1 is difficult to treat with antibiotics. In response to this growing problem, we propose to develop a point-of-care test for NAP1 using a novel DNAzyme-based technology and the classic litmus test. The unmatched advantage of this simple, instrument-free test is that it is faster to perform and easier to use. It is capable of detecting NAP1 non-invasively using stool samples with excellent sensitivity and rapid turn-around time. Unlike other diagnostic methods, manual extraction of nucleic acids or protein biomarkers is not required and minimal sample processing results in a straightforward test. The value of faster diagnosis of CDI allows healthcare providers to efficiently determine the most effective means of treatment and to reduce the costs for patient care. Our proposed point-of-care technology will further be partnered with epidemiological database tools and on demand genome sequencing-based epidemic strain detection, antimicrobial resistance gene screening, and toxin gene identification.
Programme
Operating Grant: Antimicrobial Resistance - EOI
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
349761
Name
Li Yingfu
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Developing a strain-specific test for rapid diagnosis of Clostridium difficile
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Operating Grant: Antimicrobial Resistance - EOI
Keyworddelim
Antibiotic Resistance; Bioinformatics; Biosensor; Clostridium Difficile; Diagnostics; Dnazyme; In Vitro Selection; Nap1
Abstract
Clostridium difficile causes severe diarrhoea and is the main culprit for healthcare associated infections. The emergence of a new hypervirulent strain of C. difficile, known as NAP1, in recent years has caused a significant rise in the incidence and severity of infection. This is of major concern for hospitals worldwide as the technologies for detecting NAP1 are lagging behind the spread of this epidemic strain. Consequently, the rate of C. difficile infection (CDI) has doubled in the last few years and is costing the global healthcare system more than 6 billion dollars annually. In Canada, there has been a 5-fold increase in deaths directly related to C. difficile over the last decade. The inefficient process of identifying NAP1 prolongs patient hospital stay and increases the risk of transmission to other patients. Early detection of NAP1 is crucial for preventing outbreaks and overall management of infections, particularly since compared to other CDIs NAP1 is difficult to treat with antibiotics. In response to this growing problem, we propose to develop a point-of-care test for NAP1 using a novel DNAzyme-based technology and the classic litmus test. The unmatched advantage of this simple, instrument-free test is that it is faster to perform and easier to use. It is capable of detecting NAP1 non-invasively using stool samples with excellent sensitivity and rapid turn-around time. Unlike other diagnostic methods, manual extraction of nucleic acids or protein biomarkers is not required and minimal sample processing results in a straightforward test. The value of faster diagnosis of CDI allows healthcare providers to efficiently determine the most effective means of treatment and to reduce the costs for patient care. Our proposed point-of-care technology will further be partnered with epidemiological database tools and on demand genome sequencing-based epidemic strain detection, antimicrobial resistance gene screening, and toxin gene identification.
Competitiondate
201605
Approvedterm2
0 yr 8 mths
Pinamesdelim
Li, Yingfu
Approvedterm
0 an 8 mois
Cihrcontribution2
~ $10,000~ $0~